We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis (BFR-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04633759
Recruitment Status : Completed
First Posted : November 18, 2020
Last Update Posted : October 20, 2022
Sponsor:
Collaborator:
Consortium of Multiple Sclerosis Centers
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe walking problems. BFR training involves placing a cuff on the leg being exercised in order to restrict blood flow. The cuff is attached to a specialized device that automatically detects the appropriate amount of pressure to place on the limb. Testing will occur before and after the 8-week treatment period.

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Other: Blood Flow Restriction Exercise Not Applicable

Detailed Description:

The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe walking problems. BFR training involves placing a cuff on the leg being exercised in order to restrict blood flow. The cuff is attached to a specialized device that automatically detects the appropriate amount of pressure to place on the limb. Testing will occur before and after the 8-week treatment period.

Specific Aim 1: Determine the feasibility of BFR by assessing recruitment rate, retention, adherence, satisfaction, and safety.

Hypothesis: Feasibility will be demonstrated by: 1) enrolling 20 participants in 8 months, 2) retaining at least 16 (80%) participants, 3) 80% adherence to intervention, 4) 90% satisfaction with intervention, and 5) no serious adverse events related to the intervention.

Specific Aim 2: Determine changes in knee and hip extension, hip abduction, and ankle plantarflexion muscle strength after the 8-week intervention.

Hypothesis: Following intervention there will be clinically important within-group strength changes that correspond to established minimal detectable change values and which can be characterized as having at least a moderate effect size as defined by Cohen's d.

Exploratory Aim: Explore changes in functional mobility (30-Second Sit-to-Stand, Berg Balance Scale, Timed 25-Foot Walk. 10-day average activity level) and self-report measures (12-Item MS Walking Scale, Modified Fatigue Impact Scale, MS Impact Scale-29, and Patient-Specific Functional Scale) after the 8-week intervention.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility of Low-load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis and Marked Mobility Restriction
Actual Study Start Date : February 19, 2021
Actual Primary Completion Date : October 5, 2022
Actual Study Completion Date : October 5, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Blood Flow Restriction Exercise
Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
Other: Blood Flow Restriction Exercise
Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion. Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.




Primary Outcome Measures :
  1. Change in knee extension muscle strength [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Knee extension muscle strength measured by hand-held dynamometry

  2. Change in hip abduction muscle strength [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Hip abduction muscle strength measured by hand-held dynamometry

  3. Change in ankle plantarflexion muscle strength [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Ankle plantarflexion muscle strength measured by hand-held dynamometry


Secondary Outcome Measures :
  1. Change in 30-second sit-to-stand completions [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Functional mobility test measuring the number of sit to stand cycles a participant can complete in 30 seconds

  2. Change in Berg Balance Scale [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Functional mobility test measuring the participant's ability to balance in different postures. Scores range from 0 to 56 points, with 0-20 points indicating wheelchair bound, 21-40 indicating walking with assistance, and 41-56 indicating walking independently.

  3. Change in timed 25-foot walk [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Functional mobility test measuring the time it takes a participant to walk 25 feet

  4. Change in activity level [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    10-day average of activity level as measured by a wearable activity monitor

  5. Change in 12-Item MS Walking Scale [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Self-report questionnaire measuring walking ability with scores ranging from 12 points (no difficulty walking, to 60 points (extremely limited or no walking)

  6. Change in Modified Fatigue Impact Scale [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Self-report questionnaire measuring fatigue caused by MS with scores ranging from 0 (no impact of fatigue in the past 4 weeks) to 84 (maximum impact of fatigue in the past 4 weeks)

  7. Change in MS Impact Scale-29 [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Self-report questionnaire measuring the impact of MS on daily activity with scores ranging from 29 (MS has no impact on my daily life) to 145 (MS extremely impacts my daily life)

  8. Change in MS Patient-Specific Function Scale [ Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9) ]
    Self-report questionnaire measuring the ability of the participant to do three self-identified activities. Scores of each of the 3 activities range from 0 (unable to perform) to 10 (able to perform without difficulty)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults ages 18-70
  • Neurologist-confirmed diagnosis of multiple sclerosis
  • Expanded Disability Status Scale (EDSS) 6.0 to 7.0

    • EDSS 6.0: unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting
    • EDSS 6.5: Bilateral assistance (cane or crutch) required to walk at least 20 meters with or without resting
    • EDSS 7.0: unable to walk 5 meters even with aid, essentially restricted to wheelchair; wheels self and transfers alone; up and about in wheelchair some 12 hours a day

Exclusion Criteria:

  • EDSS 7.5 or greater: Restricted to wheelchair for all mobility, unable to walk more than a few steps, even with walking aid
  • EDSS 5.5 or less: Able to walk more than 100 meters without walking aid or rest
  • Unable to provide consent or follow simple directions
  • Prior history of Deep Venous Thrombosis/ Pulmonary Embolism
  • History of peripheral vascular disease, thrombophilia or other clotting disorders
  • Patient report of easy bruising
  • Any comorbid conditions or pain that substantially affects physical function or would interfere with the participant's ability to safely complete rehabilitation (e.g. neurologic, vascular, cardiac problems, orthopedic, or ongoing medical treatments) as determined by a neurologist of physical therapist
  • Severe lower extremity spasticity as defined as Modified Ashworth scale > 2
  • Currently undergoing supervised resistance training with a physical therapist or other exercise professional
  • Use of Blood Flow Restriction currently or in the previous 3 months prior to enrollment
  • MS-related exacerbation or changes to their disease-modifying drug therapy in the month prior to enrollment
  • Inability to tolerate pressure cuff during baseline assessment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04633759


Locations
Layout table for location information
United States, Colorado
University of Colorado
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Consortium of Multiple Sclerosis Centers
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT04633759    
Other Study ID Numbers: 20-0695
205593 ( Other Grant/Funding Number: Consortium of Multiple Sclerosis Centers )
First Posted: November 18, 2020    Key Record Dates
Last Update Posted: October 20, 2022
Last Verified: October 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Colorado, Denver:
Multiple Sclerosis
Blood Flow Restriction
Resistance Training
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases